Actavis reintroduces products after FDA inspection
Actavis has reintroduced Oxycodone 15 mg and 30 mg tablets to the US market having resolved the manufacturing difficulties discovered by the US Food and Drug Administration (FDA).
The products have been off the market since December when Actavis and the FDA reached an agreement that led to the generics firm stopping distributing products made at the Little Falls, NJ, US facility.
Since then the facility has passed follow-up inspections by the FDA, which resulted in the agency approving the distribution of Oxycodone. Actavis has said it will continue to work with the FDA to ensure that more products are reintroduced in coming months.
